June 17, 2022 -- ProteoNic is licensing its 2G UNic technology for boosting therapeutic protein production to GenScript ProBio, a global contract development and manufacturing organization. The protein expression technology improves production levels across a range of mammalian host cells, selection systems, and protein targets.
Under the agreement, for which financial terms were not disclosed, GenScript ProBio will gain access to ProteoNic technology for the development of high yielding cell lines for its clients. Also, GenScript ProBio clients will profit from reduced cost of goods for their products as well as increased product development efficiency and capacity, the firms said.